| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d5fa7fed41cb61bab20df0126a9cb09 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2603-46 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-423
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-536
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D263-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D263-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C323-60 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-536
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-423 |
| filingDate |
2009-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b678f3e5facaae117c9831c0fa56032e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5af2e4f2286f632fd1528b7e5ab41c76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27e21466ec719ccf891d468cf264a598
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_284efc0fe20f80998a04b6ae17cc826d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5a67f23e4e37fcc85480f83d73d2c57 |
| publicationDate |
2010-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010009981-A1 |
| titleOfInvention |
Tetracycline Derivatives with Reduced Antibiotic Activity and Neuroprotective Benefits |
| abstract |
The present disclosure is directed to compositions and methods which utilize the tetracycline scaffold, preferably the scaffold of tetracycline or minocycline, and which significantly lack antibiotic activity. The compounds have neuroprotective attributes without interfering with the drugs capacity to pass through the blood brain barrier. These compounds have neuroprotective activity because of their inhibition of neuronal cell cycle progression. The compounds are characterized in part by a fifth ring joining positions 9 and 10. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016297779-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110204594-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014012094-A3 |
| priorityDate |
2008-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |